Chemonaive
| | | | | | |
1
|
Serous Cystadenoma/ Early Serous Borderline
|
NA
|
NA
|
None
|
64
|
NA
|
2
|
Serous Cystadenocarcinoma
|
NA
|
III
|
None
|
65
|
1 year 5 monthsa
|
3
|
Serous Papillary Carcinoma
|
G3
|
NA
|
None
|
NA
|
NA
|
4
|
Papillary Serous Cystadenocarcinoma
|
G3
|
IIIc
|
None
|
48
|
1 year 6 monthsa
|
5
|
Serous Cystadenocarcinoma NOS
|
G3
|
IIIa
|
None
|
51
|
1 year 3 monthsa
|
6
|
Serous Cystadenocarcinoma NOS
|
G3
|
NA
|
None
|
71
|
1 year 1 montha
|
Recurrent
| | | | | | |
1
|
Serous Cystadenocarcinoma NOS
|
G3
|
IIc
|
Carboplatin and Paclitaxel 2 Cycles
|
64
|
5 months until death
|
2
|
Adenocarcinoma NOS
|
NA
|
IV
|
Carboplatin and Paclitaxel 6 Cycles
|
67
|
2 years 8 months until death
|
3
|
Serous Cystadenocarcinoma NOS
|
G3
|
IIIc
|
Carboplatin/Paclitaxel/ Bevacizumab-VGEF Inhibitor (ICON7 Trial) 18 Cycles
|
55
|
5 years 6 months until death
|
4
|
Papillary Serous Cystadenocarcinoma
|
G3
|
IIIc
|
Carboplatin and Paclitaxel 6 Cycles
|
59
|
3 years 2 months until death
|
Gemicitabine and Cisplatin
|
5
|
Papillary Serous Cystadenocarcinoma
|
G3
|
IIIc
|
Carboplatin/Paclitaxel/BIBF1120- Angiogenesis Inhibitor (OVAR12 Study)
|
46
|
3 years 11 months ALC
|
6
|
Serous Cystadenocarcinoma NOS
|
G3
|
IV
|
Bevacizumab 1 cycle
|
57
|
4 years 3 months
|
Paclitaxel and Cisplatin 6 cycles
| |
ALC
|
Doxorubicin Pegylated Liposomal 6 cycles
|